Intestinal ischemia/reperfusion (I/R) injury is a serious condition in intensive care patients, resulting in severe inflammation and remote organ damage. The activation of the mammalian target of rapamycin (mTOR)/p70 ribosomal S6 kinase (p70S6K) signaling pathway exerts protective effect against ischemia/reperfusion injury. Ghrelin, an orexigenic hormone, inhibits the release of pro-inflammatory cytokines, such as interleukin (IL)-1β, tumor necrosis factor-α and IL-6. In this study, we investigated the effects of ghrelin on gut I/R injury and the regulation of the mTOR/p70S6K signaling pathway following gut I/R injury in mice. C57BL/6 mice underwent superior mesenteric artery occlusion for 45 min, followed by reperfusion for 4 h. Ghrelin was administered at the onset of reperfusion. We assessed survival, organ injury variables, pro-inflammatory cytokine expression and observed the histological changes of the small intestine and lungs. Our results revealed that the administration of ghrelin inhibited the release of certain pro-inflammatory cytokines, reduced neutrophil infiltration, attenuated organ injury and improved survival following gut I/R injury. The administration of D-Lys-GHRP6, a specific ghrelin receptor antagonist, to a certain extent, counteracted the protective effects of ghrelin in gut I/R-induced organ injury and mortality. To determine whether the beneficial effects of ghrelin following gut I/R injury are associated with the mTOR/p70S6K signaling pathway, the phosphorylation levels of mTOR and p70S6K were detected by western blot analysis. Our results revealed that mTOR and p70S6K phosphorylation increased in the tissue from the small intestine and pulmonary tissue in the animals treated with ghrelin. These findings suggest that ghrelin attenuates organ injury following gut I/R by promoting the activation of the mTOR/p70S6K signaling pathway.
Introduction
Acute intestinal ischemia is a serious abdominal emergency which is commonly observed in patients affected by trauma, burns and shock, as well as in those undergoing cardiovascular surgery and organ transplantation, resulting in a mortality rate as high as 60 to 80% (1) (2) (3) . Transient ischemia results in biological and chemical changes which lead to intestinal mucosal damage and barrier dysfunction (4) . Reperfusion can magnify the damage and even induce remote organ injuries and dysfunction through the generation of numerous pro-inflammatory cytokines and the activation of immune cells (5, 6) .
The mammalian target of rapamycin (mTOR), a type of atypical serine/threonine kinase, integrates a variety of extracellular and intracellular signals, including growth factors, nutrients, energy depletion and stress (7) . The activation of the 2 mTOR complexes, mTORC1 and mTORC2, regulates diverse functions, such as cell growth, proliferation, development, memory, longevity, angiogenesis, autophagy and innate, as well as adaptive immune responses (8) (9) (10) . mTOR controls protein synthesis through the direct phosphorylation and inactivation of a repressor of mRNA translation, eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), and through the phosphorylation and activation of p70 ribosomal S6 kinase (p70S6K), which in turn phosphorylates the ribosomal protein S6 (8, 11) . Cytokines, growth factors, amino acids, insulin, or Toll-like receptor (TLR) ligands activate mTOR and increase the phosphorylation status of 4E-BP1 and p70S6K in a rapamycin-sensitive manner (8, 11) . Certain studies have shown that the activation of the mTOR/p70S6K signaling pathway exerts a protective effect against ischemia/reperfusion (I/R) injury (12) (13) (14) (15) . Ghrelin, a 28-amino acid acylated peptide produced predominantly by the stomach, is an endogenous ligand for the growth hormone secretagogue receptor-1a (GHSR-1a) (16) . Ghrelin has been shown to possess growth hormone-releasing properties and other endocrine and non-endocrine activities, reflecting central and peripheral GHSR-1a distribution (17) (18) (19) . Previous studies have shown that ghrelin inhibits leptininduced pro-inflammatory cytokine [interleukin (IL)-1β, tumor necrosis factor (TNF)-α and IL-6] expression by human T cells and monocytes (20) and suppresses nuclear factor (NF)-κB activation in human endothelial cells (21) . It has been reported that ghrelin attenuates the formation of I/R-induced gastric lesions and other types of organ damage (22) (23) (24) (25) , with a decrease in TNF-α and IL-6 expression (26) . mTOR activation has also been shown to inhibit the production of pro-inflammatory cytokines and to enhance the release of anti-inflammatory cytokines by blocking NF-κB activation and increasing signal transducer and activator of transcription 3 (STAT3) activity (27) . Thus, in this study, we aimed to determine whether ghrelin ameliorates organ damage in a mouse model of intestinal I/R injury and to further elucidate the possible mechanisms behind its protective effects.
Materials and methods
Experimental model. Intestinal ischemia was induced in male C57BL/6J wild-type (WT) mice (16-22 g; Experimental Animal Center of Wuhan University, Wuhan, China) by clamping the superior mesenteric artery (SMA) for 45 min under general anesthesia using 0.5% pentobarbital sodium (0.2 ml/10 g) administered intraperitoneally (i.p.). The vascular clamp was released after 45 min to allow reperfusion. Upon the initiation of reperfusion, mice were resuscitated with 0.5 ml saline (administered i.p.), after which treatment commenced. The mice were randomly divided into 4 experimental groups as follows: i) ghrelin group (n=10): mice were administered (i.p.) recombinant murine ghrelin (no. 031-31, 12 nmol/kg in 0.5 ml normal saline; Phoenix Pharmaceuticals, Inc. Belmont, CA, USA); ii) vehicle group (n=10): mice were administered (i.p.) 0.5 ml normal saline; iii) ghrelin/D-Lys3-GHRP6 group (n=10): mice were administered (i.p.) a mixture of ghrelin (12 nmol/ kg in 0.25 ml normal saline) and D-Lys3-GHRP6 (no. 031-22, 12 nmol/kg in 0.25 ml normal saline; Phoenix Pharmaceuticals, Inc.); and iv) control (sham-operated) group (n=10): the animals underwent the same surgical procedure with the exception of SMA clamping. Four hours following reperfusion, the animals were anesthetized and blood (for serum) and tissue samples were harvested, stored immediately at -80˚C or soaked in 4% paraformaldehyde at 4˚C until measurements were made. In addition, experiments for the observation of survival over the course of 24 h were performed (n=11/group). All experiments were carried out in accordance with the Guide for the Care Histopathological analysis. Samples from the small intestine (impaired areas) and lungs were fixed in 4% paraformaldehyde and embedded in paraffin. Tissues were sectioned and stained with hematoxylin and eosin. Histological scoring of the depth of tissue injury was performed according to the method described in the study by Chiu et al (28) with certain modifications: score 0, no damage; score 1, subepithelial space at villous tip; score 2, loss of mucosal lining of the villous tip; score 3, loss of less than half of the villous structure; score 4, loss of more than half of the villous structure; and score 5, transmural necrosis. Sections were evaluated blindly. Lung injury was analyzed for absent, mild, moderate, or severe injury (score 0-3) based on the presence of exudates, hyperemia/congestion, neutrophilic infiltrates, intra-alveolar hemorrhage/debris and cellular hyperplasia (29) .
GHS-R and mTOR/p70S6K western blot analysis.
One hundred micrograms of protein from pulmonary and intestinal samples was fractionated on a 5-10% SDS-PAGE gel and electrotransferred onto a 0.45-µm polyvinylidene fluoride membrane. The blots were blocked with 5% skimmed milk powder in Trisbuffered saline containing 0.1% v/v Tween-20 and incubated with β-actin (1-19) (1:800; sc-1616R; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), phospho-mTOR(Ser 2448 ) mAb (1:1,000; no. 5536), mTOR (7C10) mAb ( Statistical analysis. Data were expressed as the means ± SEM and compared by analysis of variance using one-way ANOVA and the Student-Newman-Keuls test. Survival analysis was carried out using the Kaplan-Meier log-rank test. A P-value <0.05 was considered to indicate a statistically signficant difference.
Results

Ghrelin improves survival following intestinal I/R injury.
We performed survival analysis in mice receiving ghrelin at the onset of reperfusion and compared them with control mice treated with normal saline. We also established a group which was administered ghrelin and D-Lys3-GHRP-6. All the control mice died within 24 h (median survival time, 5.9 h; 95% confidence interval, 5.2-6.6) (Fig. 1) . Nine of the 11 mice treated with ghrelin, however, remained alive 24 h following gut I/R injury (median survival time, 22.9 h; 95% confidence interval, 21.2-24.7) (Fig. 1 ). Among these, 7 mice survived for >1 week (data not shown). Two of the 11 animals administered ghrelin and D-Lys3-GHRP-6 remained alive 24 h following gut I/R injury (median survival time, 17.3 h; 95% confidence interval, 14.6-20) (Fig. 1) .
Ghrelin attenuates multiple organ damage following intestinal I/R injury.
Gut I/R caused microscopic intestinal damage, such as mucosal destruction, loss of villi and epithelial cell apoptosis, hemorrhaging and infiltration of inflammatory cells (Fig. 2B) . Treatment with ghrelin significantly improved these microscopic alterations (Fig. 2C) . Similarly, lung injury characterized by the disruption of lung architecture, extravasation of red blood cells, and accumulation of inflammatory cells was present in the I/R-vehicle treated animals (Fig. 3B) . The ghrelin-treated mice displayed a marked reduction in the number of infiltrating inflammatory cells and an improvement in lung architecture (Fig. 3C ). In the gut and lungs, tissue injury was slightly ameliorated in the mice treated with ghrelin and D-Lys3-GHRP6 (Figs. 2D and 3D ). To evaluate remote organ injury at the biochemical level, we assayed the serum activities of AST, ALT, LDH, creatinine and urea nitrogen. Compared with the sham-operated animals, serum ALT, AST, LDH, creatinine and urea nitrogen levels in the animals with I/R injury in the vehicle-treated group increased by 13.79-, 8.58-, 5.57-, 4.12-and 5.19-fold, respectively (P<0.05) (Fig. 4) . The administration of ghrelin decreased ALT, AST, LDH, creatinine and urea nitrogen levels by 59.7, 67.4, 50.6, 63.9 and 71.6%, respectively (P<0.05) (Fig. 4) compared with the vehicle-treated group. When the animals with I/R injury were simultaneously administered ghrelin and its antagonist, D-Lys3-GHRP6, the plasma levels of ALT, AST, LDH, creatinine and urea nitrogen decreased by 48, 34.1, 29.6, 19.5 and 39.6%, respectively (P<0.05) (Fig. 4) .
MPO activity is an indicator of neutrophil infiltration. As demonstrated in Fig. 5 , gut I/R induced a significant increase in intestinal and pulmonary MPO activity in the vehicle-treated mice as compared with the sham-operated animals. Treatment with ghrelin significantly inhibited the increase in intestinal (Fig. 5A ) and pulmonary (Fig. 5B ) MPO activity following gut I/R. These results demonstrate that ghrelin attenuates the influx of neutrophils into the gut and lungs following gut I/R injury.
Ghrelin suppresses pro-inflammatory responses following gut I/R injury. Pro-inflammatory cytokines play an important role in the injury of remote organs following gut I/R. To investigate whether the cytokines, TNF-α, IL-1β and IL-6, were affected by treatment with ghrelin, we determined their expression levels in the blood, intestine and lungs. We found that the cytokine levels in the serum increased significantly following intestinal I/R injury (TNF-α by 14.5-fold, IL-1β by 27.1-fold and IL-6 by 20.4-fold), while the administration of ghrelin markedly reduced the pro-inflammatory response (by 75.3, 90.2 and 71.9%, respectively) ( Fig. 6A-C) . We also measured TNF-α, IL-1β and IL-6 production in the small intestine and lungs using ELISA. We observed similar suppressive effects of ghrelin on cytokine levels in tissue from the small intestine ( Fig. 6D-F) , as well as in pulmonary tissue (Fig. 6G-I) . As shown by our results, the levels of TNF-α, IL-1β and IL-6 significantly decreased in the tissue from the small intestine (by 65.3, 62.7 and 53%) (Fig. 6D-F ) and lung tissue (by 50, 61.7 and 51.1%) (Fig. 6G-I) following treatment with ghrelin. 
Antagonistic effect of D-Lys3-GHRP-6 on ghrelin-mediated tissue protection following intestinal I/R injury. D-Lys3
-GHRP-6 is a ghrelin receptor antagonist. It was used for further confirmation of the protective effects of ghrelin in our experimental model. We observed that the levels of the proinflammatory cytokines, TNF-α, IL-1β and IL-6, in the lungs of the animals treated with D-Lys3-GHRP6 did not differ significantly from those in the animals in the vehicle-treated group. The levels of TNF-α, IL-1β and IL-6 in pulmonary tissue decreased by 32.6, 21.5 and 17.2%, respectively in the group treated with D-Lys3-GHRP6 compared with the vehicle-treated group (Fig. 6G-I ). As shown in Fig. 6A -C, the levels of TNF-α, IL-1β and IL-6 in the serum decreased by 25.7, 48.7 and 49.9%, respectively in the group treated with D-Lys3-GHRP6 compared with the vehicle-treated group. In the tissue from the small intestine, the TNF-α, IL-1β and IL-6 levels were reduced by 57.9, 46 and 43.5%, respectively in the group treated with D-Lys3-GHRP6 compared with the vehicle-treated group (Fig. 6D-F) . However, the levels of IL-6 in the serum and tissue from the small intestine, as well as the TNF-α levels in the tissue from the small intestine markedly decreased. We hypothesized that D-Lys3-GHRP6 has a partial inhibitory effect on GHSR-1a in organisms.
Ghrelin promotes the activation of the mTOR signaling pathway in the small intestine and lungs. In order to deter- mine whether ghrelin mediates the activation of the mTOR signaling pathway, we extracted protein from the injured small intestine and lungs and detected phosphorylated mTOR and p70S6K levels by western blot analysis. mTOR and p70S6K phosphorylation increased in the tissue from the small intestine and pulmonary tissue in the animals treated with ghrelin compared with the vehicle-treated group (Fig. 7) .
Discussion
Intestinal I/R injury is a serious complication in a variety of pathological conditions and surgical procedures, including sepsis, strangulated bowel, vascular surgery and hemorrhagic shock (30) . The activation of immune cells adjacent to the huge endothelial cell surface area of the intestinal microvasculature produces initially local and then systemic inflammatory responses, which lead to severe tissue damage (26) . Ghrelin is an endogenous ligand for GHSR-1a (16) , and GHSR-1a expression is present in the brain stem, pituitary gland, hypothalamus, heart, blood vessels, lungs, stomach, pancreas, intestines, kidneys and adipose tissue (31) (32) (33) . Therefore, ghrelin plays various physiological roles in both the central nervous system and the periphery (19) , such as the regulation of pituitary hormone secretion, feeding, energy homeostasis, gastrointestinal function, as well as in the cardiovascular and immune system (34) (35) (36) . In a previous study, Wu et al (26) showed that plasma levels of ghrelin were significantly reduced and that the administration of exogenous ghrelin attenuated local and remote organ injury following gut I/R in rats. In the present study, we established a mouse model of intestinal I/R (i.e., superior mesenteric artery occlusion) and found that the indicators of tissue injury (MPO activity) and organ dysfunction (ALT, AST, LDH, creatinine and urea nitrogen levels) were significantly decreased in the ghrelin-treated mice following gut I/R. The levels of the pro-inflammatory cytokines, TNF-α, IL-1β and IL-6, were also decreased in the ghrelin-treated group. When the mice were administered D-Lys3-GHRP-6 (a ghrelin receptor antagonist), the decrease in the levels of some of the abovementioned indicators was insignificant; no statistically significant difference was observed in the levels of some of these indicators between the group treated with D-Lys3-GHRP-6 and the vehicle-treated group. These differences were also observed during histological and and survival analysis. Therefore, our results further confirm the protective role of ghrelin during intestinal I/R injury in mice. mTOR is a type of atypical serine/threonine kinase which integrates various extracellular and intracellular signals, including metabolism, growth, survival, aging, synaptic plasticity, immunity and memory (10) . The activation of the mTOR/p70S6K pathway is a critical event in the modulation of protein synthesis and the regulation of cell growth (37) (38) (39) . However, certain studies have shown that phosphorylated forms of Akt and p70S6K are significantly decreased in transient focal cerebral ischemia, resulting in the suppression of the initiation step of protein synthesis and cell growth (41, 42) . Thus, the activation of the mTOR/p70S6K pathway exerts a protective effect against ischemic brain injury (12,13,43). In our study, the same phenomenon was observed in a mouse model of gut I/R; the phosphorylation levels of mTOR and p70S6K decreased in the tissue from the small intestine and pulmonary tissue following I/R. Recently, Aoyagi et al (46) used transgenic (Tg) mice with cardiac-specific overexpression of mTOR (mTOR-Tg mice) to examine I/R injury and found that mTOR overexpression inhibited necrosis during I/R injury. In our study, we observed that mTOR and p70S6K phosphorylation levels increased and that mucosal destruction, loss of villi, epithelial cell apoptosis in the small intestine and the disruption of lung architecture were alleviated in the animals administered ghrelin following gut I/R. These findings suggest that the activation of the mTOR/p70S6K signaling pathway inhibits cellular necrosis, and thus protects tissue architecture from destruction during gut I/R.
In addition to cell damage caused by ischemia and hypoxia, excessive and sustained inflammatory responses during reperfusion also play an important role in tissue damage. The expression of pro-inflammatory genes is regulated by transcriptional mechanisms. NF-κB is a critical transcription factor required for the maximal expression of several cytokines involved in the pathogenesis of acute lung injury and gut I/R injury (47, 48) . Moreover, mTOR negatively regulates the NF-κB pathway (27, 49) . In monocytes and macrophages, mTOR inhibits NF-κB-dependent pro-inflammatory cytokine IL-12 production and activates STAT3-dependent anti-inflammatory IL-10 production (27, 44, 45) . Previous studies have shown that ghrelin inhibits leptin-induced pro-inflammatory cytokine (IL-1β, TNF-α and IL-6) expression by human T cells and monocytes (20) and suppresses NF-κB activation in human endothelial cells (21) . Recently, Aoyagi et al (46) reported that the expression of IL-6 and TNF-α in mTOR-Tg mouse hearts was lower than that in WT mouse hearts following cardiac I/R (46) . These data indicate that the activation of the mTOR signaling pathway plays an anti-inflammatory role. Additionally, it has been reported that central ghrelin administration promotes a marked increase in the phosphorylated (active) form of mTOR and its downstream targets, pS6K1 and p6 in the arcuate nucleus of the hypothalamus (50) . The data from the present study demonstrate that the intraperitoneal administration of ghrelin promotes the activity of the mTOR signaling pathway, inhibits some pro-inflammatory cytokine release and reduces neutrophil infiltration following gut I/R. Based on the above findings, it can be concluded that ghrelin promotes the activation of the mTOR/p70S6K signaling pathway and inhibits the NF-κB pathway in during inflammation; therefore, ghrelin reduces inflammatory responses, ameliorates organ damage and reduces mortality in the intestinal I/R injury model. Thus, ghrelin may be a potential therapeutic agent in various inflammatory disorders induced by gut I/R.
